24
2020-06
SHANGHAI, June 24, 2020 -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact,
17
2020-03
Shanghai, China—InxMed (Shanghai) Co., Ltd.(“InxMed” or “Company”), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today that the company has dosed first patient in its Phase Ib clinical trial of IN10018 as monotherapy and in combination with MEKi in the patients either with metastatic uveal melanoma or NRAS mutant metastatic melanoma at The University of Texas M. D. Anderson Cancer Center, United States.
20
2019-12
InxMed Receives Approval to Initiate Phase I Clinical Trial in China for IN10018
Shanghai, China—InxMed (Shanghai) Co., Ltd.(“InxMed” or “Company”), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today that the Company has obtained IND (Investigational New Drug) clearance for IN10018, a proprietary focal adhesion kinase (FAK) inhibitor, from China National Medical Products Administration (NMPA) to initiate Phase I clinical trial in patients with locally advanced or metastatic gastric cancer. Previously IN10018 has opened IND in the United States in August 2019.
12
2019-10
InxMed Announces Clinical Collaboration to Evaluate IN10018 in Combination with Cobimetinib
Shanghai, China – InxMed (Shanghai) Co., Ltd., (“InxMed” or “Company”) today announced that the company has entered into a clinical collaboration with Roche (F. Hoffmann-La Roche Ltd.,) to evaluate IN10018, a proprietary focal adhesion kinase (FAK) inhibitor in combination with Roche’s Cobimetinib, an inhibitor of mitogen-activated protein kinase (MEK).
20
2019-09
InxMed Receives US FDA IND Approval to Initiate Clinical Trial for IN10018
Shanghai, China—InxMed (Shanghai) Co., Ltd. (“InxMed” or “Company”), announced that the Company has obtained FDA (Food and Drug Administration) IND clearance for IN10018, a proprietary focal adhesion kinase (FAK) inhibitor. This is InxMed's first IND opening approved by FDA, which reflects the company's superior R&D capability.
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE